List of works - Katerina Politi

A mouse model of uterine leiomyosarcoma

scientific article

A mouse plasma peptide atlas as a resource for disease proteomics

scientific article published on 3 June 2008

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

scientific article

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

scientific article

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.

scientific article published on 22 March 2018

DOK2 inhibits EGFR-mutated lung adenocarcinoma

scientific article

De novo selection of oncogenes

scientific article published on 16 December 2013

Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor

scientific article

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors

scientific article

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

scientific article

EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer.

scientific article

ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas

scientific article

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

scientific article published on 12 January 2018

Early shear stress signaling on vascular endothelium by a modified partial carotid ligation model.

scientific article published on 13 September 2011

Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer

scientific article

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

scientific article published on 9 December 2009

Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma

scientific article

Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors

scientific article published on 18 August 2008

Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse

scientific article published in February 2014

Genome-Wide RNA Interference: Functional Genomics in the Postgenomics Era.

scientific article published in September 2017

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

scientific article published on 5 September 2012

How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers ⬇️

scientific article published on January 24, 2011

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

scientific article published on 12 October 2017

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines

scientific article published on 8 October 2017

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

scientific article

Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas

scientific article published in April 2015

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma

scientific article

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

scientific article

Lung cancer in the era of precision medicine

scientific article published in May 2015

Lung cancer signatures in plasma based on proteome profiling of mouse tumor models

scientific article

MYCxing it up with FGFR1 in squamous cell lung cancer

scientific article

Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium

scientific article

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma

scientific article published on 04 October 2016

Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice

scholarly article

Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance

scientific article published on 03 June 2013

Noncovalent wild-type-sparing inhibitors of EGFR T790M

scientific article published on 10 December 2012

Notch in mammary gland development and breast cancer

scientific article published in October 2004

Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras

scholarly article

Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells

scientific article published on 21 June 2016

Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer

scientific article

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

scientific article published on 28 July 2016

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer

scientific article

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

scientific article

The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2).

scientific article published on 7 December 2017

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic

scientific article published in June 2015

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells

scientific article published on 19 April 2017

Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis.

scientific article

Translational therapeutics in genetically engineered mouse models of cancer

scientific article published on February 2014

Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer ⬇️

scientific article published on February 8, 2012

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.

scientific article published on 6 June 2018

List of works by Katerina Politi

A mouse model of uterine leiomyosarcoma

A mouse plasma peptide atlas as a resource for disease proteomics

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.

DOK2 inhibits EGFR-mutated lung adenocarcinoma

De novo selection of oncogenes

Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer.

ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

Early shear stress signaling on vascular endothelium by a modified partial carotid ligation model.

Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma

Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors

Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse

Genome-Wide RNA Interference: Functional Genomics in the Postgenomics Era.

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers ⬇️

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

Lung cancer in the era of precision medicine

Lung cancer signatures in plasma based on proteome profiling of mouse tumor models

MYCxing it up with FGFR1 in squamous cell lung cancer

Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma

Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice

Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance

Noncovalent wild-type-sparing inhibitors of EGFR T790M

Notch in mammary gland development and breast cancer

Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras

Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells

Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2).

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells

Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis.

Translational therapeutics in genetically engineered mouse models of cancer

Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer ⬇️

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.